Search

This mixed methods program evaluation study was designed to assist faculty in better understanding students' multicultural and social justice training experiences, with the goal of improving program curriculum and instruction. It also offers a model for counselor educators to assess student experiences and to make changes that center social justice. A total of 139 first-semester students and advanced practicum students responded to an online survey. The Consensual Qualitative Research-Modified (CQR-M) method was used to analyze brief written narratives. The Multicultural Counseling Competence and Training Survey (MCCTS) and the Advocacy Competencies Self-Assessment Survey (ACSA) were used to triangulate the qualitative data. Qualitative findings revealed student growth in awareness, knowledge, skills, and action, particularly for advanced students, with many students reporting a desire for more social justice instruction. Some students of color reported microaggressions and concerns that training centers White students. Quantitative analyses generally supported the qualitative findings and showed advanced students reporting higher multicultural and advocacy competencies compared to beginning students. Implications for counselor education are discussed. [ABSTRACT FROM AUTHOR]

Four new acyclic ligands, Bn-[H.sub.3]nonapa (3), [H.sub.3]nonapa (4), pN[O.sub.2]-Bn-[H.sub.3]nonapa (10), and Bn[H.sub.3]trenpa (7), were synthesized and studied with nonradioactive [In.sup.3+] and with radioactive [sup.111][In.sup.3+]. The coordination of these ligands to [In.sup.3+] was confirmed by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. Radiolabeling experiments were performed with [sup.111][In.sup.3+]; these demonstrated [H.sub.3]nonapa (4) to be the best indium ligand of those studied herein, achieving radiochemical yields of ~97% in 10 min at ambient temperature, and stability to transchelation in mouse serum of 44.5% ± 25.9% after 24 h. Although the radiolabeling kinetics of [H.sub.3]nonapa (4) were excellent, serum stability results were inferior to the previously studied ligands DOTA, DTPA, and [H.sub.4]octapa, suggesting that the presented ligands may find their optimum radiopharmaceutical applications with isotopes other than [sup.111]In. Owing to the high denticity of these ligands (9-10 coordinate), they may realize their potential with large ion isotopes such as [sup.177]Lu, [sup.86/90]Y, and [sup.225]Ac. Key words: radiopharmaceuticals, coordination chemistry, radiometals, multidentate ligands, picolinates. Quatre nouveaux ligands acycliques Bn-[H.sub.3]nonapa (3), [H.sub.3]nonapa (4), p-N[O.sub.2]-Bn[H.sub.3]nonapa (10) et Bn-[H.sub.3]trenpa (7) ont ete synthetises et etudies a l'aide de l'ion [In.sup.3+], non radioactif, et de l'ion [sup.111][In.sup.3+], radioactif. La coordination de ces ligands avec l'ion [In.sup.3+] a ete confirmee par spectrometrie de masse de haute resolution et spectroscopie de resonance magnetique nucleaire. Des experiences de radiomarquage avec l'ion [sup.111][In.sup.3+] ont ete realisees et ont montre que [H.sub.3]nonapa (4) etait le plus performant des quatre ligands etudies, de par son rendement chimique (environ 97%, apres 10 minutes et a la temperature ambiante) et sa stabilite a l'egard de la transchelation dans du serum de souris (44,5% [+ or-] 25,9% des ligands intacts apres 24 h). Bien que la cinetique du radiomarquage de [H.sub.3]nonapa (4) fut excellente, les resultats de la stabilite de ce dernier dans le serum ont ete inferieurs a ceux obtenus pour les ligands precedemment etudies (DOTA, DTPA et [H.sub.4]octapa), ce qui signifie que les ligands etudies ici pourraient etre utilises de facon optimale dans le domaine pharmaceutique avec des isotopes autres que l'indium [sup.111]In. En raison de la denticite elevee de ces ligands (coordinence de 9 a 10), ils pourraient atteindre tout leur potentiel avec des isotopes ioniques lourds tels que [sup.177]Lu, [sup.86/90]Y et [sup.225]Ac. [Traduit par la Redaction] Mots-cles : radiopharmaceutiques, chimie de coordination, radiometaux, ligands multidentates, picolinates., Introduction The radiometal [sup.111]In is a versatile isotope that has been commonly used for single photon emission computed tomography (SPECT) and Auger electron/[β.sup.-] therapy, typically withtargeting vectors such as peptides, [...]

Copyright of Canadian Journal of Chemistry is the property of Canadian Science Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The hepatocyte growth factor (HGF) binding antibody rilotumumab (AMG102) was modified for use as a 89 Zr-based immuno-PET imaging agent to noninvasively determine the local levels of HGF protein in tumors. Because recent clinical trials of HGF-targeting therapies have been largely unsuccessful in several different cancers (e.g., gastric, brain, lung), we have synthesized and validated 89 Zr-DFO-AMG102 as a companion diagnostic for improved identification and selection of patients having high local levels of HGF in tumors. To date, patient selection has not been performed using the local levels of HGF protein in tumors. Methods: The chelator p -SCN-Bn-DFO was conjugated to AMG102, radiolabeling with 89 Zr was performed in high radiochemical yields and purity (>99%), and binding affinity of the modified antibody was confirmed using an enzyme-linked immunosorbent assay (ELISA)-type binding assay. PET imaging, biodistribution, autoradiography and immunohistochemistry, and ex vivo HGF ELISA experiments were performed on murine xenografts of U87MG (HGF-positive, MET-positive) and MKN45 (HGF-negative, MET-positive) and 4 patient-derived xenografts (MET-positive, HGF unknown). Results: Tumor uptake of 89 Zr-DFO-AMG102 at 120 h after injection in U87MG xenografts (HGF-positive) was high (36.8 ± 7.8 percentage injected dose per gram [%ID/g]), whereas uptake in MKN45 xenografts (HGF-negative) was 5.0 ± 1.3 %ID/g and a control of nonspecific human IgG 89 Zr-DFO-IgG in U87MG tumors was 11.5 ± 3.3 %ID/g, demonstrating selective uptake in HGF-positive tumors. Similar experiments performed in 4 different gastric cancer patient-derived xenograft models showed low uptake of 89 Zr-DFO-AMG102 (∼4-7 %ID/g), which corresponded with low HGF levels in these tumors (ex vivo ELISA). Autoradiography, immunohistochemical staining, and HGF ELISA assays confirmed that elevated levels of HGF protein were present only in U87MG tumors and that 89 Zr-DFO-AMG102 uptake was closely correlated with HGF protein levels in tumors. Conclusion: The new immuno-PET imaging agent 89 Zr-DFO-AMG102 was successfully synthesized, radiolabeled, and validated in vitro and in vivo to selectively accumulate in tumors with high local levels of HGF protein. These results suggest that 89 Zr-DFO-AMG102 would be a valuable companion diagnostic tool for the noninvasive selection of patients with elevated local concentrations of HGF in tumors for planning any HGF-targeted therapy, with the potential to improve clinical outcomes., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)